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Purpose: Reasons for worldwide variability in the burden of primary malignant brain and 
central nervous system (CNS) tumors remain unclear. This study compares the incidence 
and survival of malignant brain and CNS tumors by selected histologic types between 
the United States (US) and Taiwan.
Methods: Data from 2002 to 2010 were selected from two population-based cancer 
registries for primary malignant brain and CNS tumors: the Central Brain Tumor Registry 
of the United States and the Taiwan Cancer Registry. Two registries had similar process 
of collecting patients with malignant brain tumor, and the quality of two registries was 
comparative. The age-adjusted incidence rate (IR), IR ratio, and survival by histological 
types, age, and gender were used to study regional differences.
results: The overall age-adjusted IRs were 5.91 per 100,000 in the US and 2.68 per 
100,000 in Taiwan. The most common histologic type for both countries was glioblas-
toma (GBM) with a 12.9% higher proportion in the US than in Taiwan. GBM had the 
lowest survival rate of any histology in both countries (US 1-year survival rate = 37.5%; 
Taiwan 1-year survival rate  =  50.3%). The second largest group was astrocytoma, 
excluding GBM and anaplastic astrocytoma, with the distribution being slightly higher in 
Taiwan than in the US.
conclusion: Our findings revealed differences by histological type and grade of primary 
malignant brain and CNS tumors between two sites.
Keywords: malignant brain and central nervous system tumors, incidence, survival, cBTrUs, Taiwan cancer 
registry
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inTrODUcTiOn
Differences in brain and central nervous system (CNS) tumor 
incidence have been reported between countries worldwide. In 
general, the incidence of brain and CNS tumors of the Western 
world is higher than that of the Eastern world (1) and higher in 
developed countries compared with less developed countries 
(2, 3). Differences are also seen between ethnic and racial groups 
within the same country. For example, brain tumors are less 
common among Asian Americans compared with Whites in the 
United States (US) and United Kingdom (UK) (4, 5).
Differences in survival of brain and CNS tumors also exist. 
Studies conducted in the US show that differences in survival 
are mainly due to the variation in histologic type and grade 
after adjusting for age, sex, and treatment (6–8). Geographical 
differences in the delivery of care to cancer patients within the 
UK might be reflected in differences of long-term survival (9). 
A comparison study found a higher survival rate among the 
most common pediatric CNS tumors in the UK compared with 
those in the US (10); however, the reasons for this difference in 
observed survival are not known.
The etiology attributed to these differences is not entirely clear. 
Several factors, such as differences in cancer screening practices, 
availability and quality of medical treatment, and age distribution, 
could result in regional differences in the burden of brain cancer 
(3, 8, 9, 11–14). However, very few studies examine the difference 
in incidence and survival of brain and CNS tumors directly across 
the countries (15). Although ethnicity, cultural beliefs, lifestyles, 
socioeconomic conditions, and health-care systems are quite 
different between the US and Taiwan, the methods and processes 
of collecting data on newly diagnosed cancer cases are similar. 
Investigating the differences and similarities of two heterogene-
ous groups while controlling the variation in ascertaining cancer 
cases could help further the knowledge of the epidemiology of 
malignant brain and CNS tumors. Therefore, the aim of this study 
is to compare the incidence and survival of malignant brain and 
CNS tumors by selected histologic types between the US and 
Taiwan using population-based data from both countries.
MaTerials anD MeThODs
ethics statement
This study was approved by the Taipei Medical University Joint 
Institutional Review Board and conducted under the approval 
from the University Hospitals Case Medical Center Institutional 
Review Board. In addition, Central Brain Tumor Registry of the 
United States (CBTRUS) adheres to a confidentiality agreement 
per the Centers for Disease Control (CDC)/National Program 
of Cancer Registries (NPCR). Confidentiality of the data from 
Taiwan was assured by the data regulations of the Health and 
Welfare Data Science Center (HWDC), Ministry of Health and 
Welfare, Executive Yuan, Taiwan.
Data sources
Two major data sources were used in this study, compiling all 
primary malignant brain and CNS tumor diagnosed from 2002 to 
2010 from the US and Taiwan. The CBTRUS is very comprehensive 
and is the largest aggregation of population-based incidence data 
on primary brain and CNS tumors in the US. CBTRUS contains 
incidence data from 50 central cancer registries [45 NPCR and 5 
Surveillance, Epidemiology, and End Results (SEER)] represent-
ing ~98% of the US population (4).
The Taiwan Cancer Registry (TCR) is organized and funded 
by the Ministry of Health and Welfare of the executive branch 
of the central government since 1979. Following the enactment 
of the Cancer Control Act in 2003, all hospitals are mandated to 
submit cancer data to TCR. Additionally, TCR data are subjected 
to periodic quality control audits and are processed according to 
the standard guidelines of the International Agency for Research 
on Cancer, resulting in 2-year time lag between collection and 
publication of data. It is also overseen by an advisory board run by 
the National Public Health Association that works to standardize 
terminology, coding, and procedures for the registry.
Information on individual survival after diagnosis is not avail-
able in the CBTRUS or TCR data sets, so survival information 
was obtained from 18 SEER registries in the US and the National 
Death Registry in Taiwan for the same years. The 18 SEER 
registries cover ~26% of the US population, and the TCR covers 
~100% of the Taiwanese population.
Patient selection
The same criteria were used to select patients with malignant brain 
and CNS tumors from both datasets. The cases were restricted to 
the International Classification for Disease, Oncology, third edi-
tion (16) (ICD-O-3) behavior codes (malignant only), and then 
histology codes as noted. We finally selected the most common 
histology groupings for inclusion in our analysis, which includes 
183,740 (92.82% of total) in the CBTRUS data and 5,855 (92.54% 
of total) in the TCR in the final analysis. The percentage of micro-
scopically confirmed (MC) cases of malignant brain and CNS 
tumors was ~90% of both sites in the study period (CBTRUS: 
89.48% versus TCR: 89.68%) The detailed information relevant 
to the quality of two registries were shown in the Table S1 in 
Supplementary Material.
The 14 histological groups were chosen for comparison: 
astrocytoma [excluding glioblastoma (GBM) and anaplastic 
astrocytoma (AA)] (ICD-O-3 histology codes: 9381, 9384, 
9400, 9410, 9411, 9420, 9421, 9424), AA (ICD-O-3 histology 
code: 9401), GBM (ICD-O-3 histology codes: 9440–9442), 
oligodendroglioma (ICD-O-3 histology code: 9450), anaplastic 
oligodendroglioma (ICD-O-3 histology codes: 9451, 9460), oli-
goastrocytic tumors (ICD-O-3 histology code: 9382), ependy-
mal tumors (ICD-O-3 histology codes: 9391–9393), glioma 
malignant (not otherwise specified, NOS) (ICD-O-3 histology 
code: 9380), neuronal and mixed neuronal glial tumors (ICD-
O-3 histology codes: 8680, 8693, 9505, 9522, 9523), embryonal 
tumors (ICD-O-3 histology codes: 8963, 9364, 9470–9474, 9480, 
9490, 9500, 9501, 9502, 9508), nerve sheath tumors (ICD-O-3 
histology codes: 9540, 9560, 9561, 9571), malignant meningi-
oma (ICD-O-3 histology codes: 9530, 9538, 9539), lymphoma 
and hematopoietic neoplasms (ICD-O-3 histology codes: 9590, 
9591, 9596, 9650–9655, 9659, 9661–9667, 9670, 9671, 9673, 
9675, 9680, 9684, 9687, 9690, 9691, 9695, 9698, 9699, 9701, 
9702, 9705, 9714, 9719, 9727–9729, 9731, 9733, 9734, 9740, 
FigUre 2 | annual age-adjusted incidence rates of malignant brain 
and cns tumors by age and country, 2002–2010.
FigUre 1 | annual age-adjusted incidence rates of malignant brain 
and cns tumors by year and country, 2002–2010.
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9741, 9750, 9754–9758, 9760, 9823, 9826, 9827, 9832, 9837, 
9860, 9861, 9866, 9930), and germ cell tumors, cysts, and 
heterotopias (ICD-O-3 histology codes: 8020, 8440, 9060, 9061, 
9064, 9065, 9070–9072, 9080–9085, 9100, 9101) (Detailed cod-
ing is provided in Table S2 in Supplementary Material). These 
histologic groups are based on definitions used by CBTRUS in 
their annual statistical report (4).
statistical analysis
In this study, we presented age-adjusted incidence rates (IRs), 
adjusted to the World Health Organization (WHO) 2000–2025 
World Standard Population. We also calculated the IR ratios 
to compare IRs of selected tumors by country and sex. The age 
groups were categorized into children (aged 0–14  years), ado-
lescents and young adults (AYA; aged 15–39 years), adults (aged 
40–64 years), and the elderly (aged 65 years and above). The 1-, 
2-, and 5-year survival rates were computed based on the life-
table (actuarial) methods in both registries and represented the 
percentage of individuals who have survived during a specified 
time period. Because the prognosis for brain and CNS tumors 
varies dramatically depending not only on the histologic grade 
and anatomic location but also on age and sex of patient, IRs by 
histology, sex, age, and primary site and survival rate by histology 
were additionally presented to enhance displaying the similarity 
and dissimilarity between two countries. The analyses of the two 
registries were done separately while following the same protocol. 
Analyses of CBTRUS and SEER registry data were conducted 
using SEER*Stat 8.04 statistical software. Statistical analyses of 
TCR data were conducted using SAS/STAT, Version 9.3, and the 
STATA 12 (StataCorp LP, College Station, TX, USA) software 
packages.
resUlTs
Overall incidence rates
Between 2002 and 2010, there were 183,740 newly diagnosed 
cases of malignant brain and CNS tumors in the US and 5,855 
in Taiwan. IRs by year of diagnosis are presented in Figure  1. 
The overall age-adjusted IRs were 5.91 per 100,000 in the US and 
2.68 per 100,000 in Taiwan. The IRs were relatively constant for 
each country over the study period, ranging from 5.93 to 6.01 per 
100,000 in the US and from 2.63 to 2.92 per 100,000 in Taiwan 
(Table S3 in Supplementary Material). IRs by age group ranged 
from 3.05 to 19.61 per 100,000 in the US. The IR for AYA was the 
lowest followed by children, adults, and the elderly in the US, with 
a similar pattern in Taiwan (Figure 2).
Distribution of Tumors by histology
The most common histologic group for both countries was GBM; 
47.8% of all tumors in the US and 34.9% of all tumors in Taiwan 
(Figure 3). The second largest histologic group was astrocytoma 
(excluding GBM and AA), which made up a slightly higher pro-
portion of all tumors in Taiwan (15.9%) than in the US (13.6%). 
The third largest histologic group was CNS lymphoma in the US 
(6.7%) and AA in Taiwan (5.9%).
incidence rates and incidence rate ratio
Overall, the IRs by histologic groups were significantly greater 
in the US compared with Taiwan (Table S4 in Supplementary 
Material). The IR of GBM was 2.9 times in the US (2.48 per 
100,000) as compared with Taiwan (0.85 per 100,000). The sec-
ond highest histologic group was astrocytoma (excluding GBM 
and AA) in both the US (0.95 per 100,000) and Taiwan (0.44 per 
100,000) (Table S4 in Supplementary Material).
The IRs by histologic group also varied based on age group, 
and these results are shown in Tables S5A,B in Supplementary 
Material. The most common childhood tumor was the astrocy-
toma group (excluding GBM and AA) in the US, but in Taiwan 
it was the embryonal tumor group. For AYA, the most common 
tumor group was astrocytoma (excluding GBM and AA) in the 
US as well as in Taiwan. GBM was the most common histologic 
group in adults and the elderly in both countries.
The IRs by histology were higher in males than females in both 
countries, except for oligodendroglioma, ependymal tumors, 
FigUre 4 | incidence rate ratios by country (Us:Taiwan) for histologies, 2002–2010.
FigUre 3 | Distribution of malignant brain and cns tumors by histology and country, 2002–2010.
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glioma malignant, NOS, nerve sheath tumors, and meningioma 
in the US (Table S6 in Supplementary Material). The IR ratio 
(male:female) was similar (1.18 in US versus 1.34 in Taiwan) 
(Figure 5). In general, the pattern of male:female ratio of selected 
histological group was quite similar between two registries; how-
ever, we observed a greater variation in Taiwan.
FigUre 5 | incidence rate ratios by sex (male:female) and country for histologies, 2002–2010.
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In the US, the IRs by primary site were highest for tumors 
located in the frontal lobe (1.34 per 100,000), followed by tumors 
located in other brain (i.e., all other sites within the brain), tem-
poral lobe, parietal lobe, and the other parts of brain and CNS 
(Table S7 in Supplementary Material). In Taiwan, the IRs were 
highest for tumors located in other brain (0.70 per 100,000), 
followed by tumors located in the frontal lobe, temporal lobe, 
and cerebrum.
survival rates by histology
In general, the overall survival rates for selected tumors were 
lower in the US than in Taiwan. However, there was a large vari-
ation in survival depending upon tumor histology (Table 1). For 
example, GBM had the lowest 1-year survival rate in both coun-
tries (37.5% in the US and 50.3% in Taiwan), and CNS lymphoma 
was the second lowest in US but the third lowest in Taiwan (1-year 
survival rate of 51.4% in the US and 60.9% in Taiwan).
DiscUssiOn
Our findings revealed that there were some differences in the 
incidence of and survival after diagnosis with malignant brain 
and CNS tumors in the US compared with that in Taiwan. We 
found the age-adjusted incidence of malignant brain and CNS 
tumors in the US to be greater than that in Taiwan; however, 
the survival rate in the US was slightly lower than that in 
Taiwan. From 2002 to 2010, there were no significant changes 
in IRs in the US and Taiwan. The distribution by histologic 
type varied between the two countries, although GBM had the 
highest frequency in both countries. The overall IR ratio by sex 
was similar in both countries, although the male:female ratios 
were not consistent in certain histologic groups. Incidence 
by age and histology was also very similar in both countries, 
except for the most common tumor in children: astrocytoma 
(excluding GBM and AA) in the US while embryonal tumors 
in Taiwan.
Regional differences in IRs have been reported for many 
other types of cancers (11, 12, 15, 17–19) and brain tumor (14). 
Most of these studies suggested the difference was a result of a 
combination effect of differing in screening practices, dispari-
ties in lifestyle, race, and hereditary factors. In this study, the 
lower age-adjusted IRs of malignant brain and CNS tumors in 
Taiwan was less likely due to differences in imaging diagnostic 
techniques as the standards for imaging for brain and CNS 
tumors was the same in both countries. Many epidemiologic 
studies have attempted to identify the potential risk factors for 
brain tumors (9, 14, 20). Only ionizing radiation exposure and 
certain genetic syndromes were well-defined risk factors for 
malignant glioma, and history of allergy provides some decrease 
in risk, but there was no established risk factor that accounts for 
a majority of tumors (21). This current study tended minimizes 
the bias due to diagnostic practice, cases ascertainment, and 
access to care of brain tumor cases as compared the US with 
Taiwan; however, we still found the dissimilarity of cancer inci-
dence between two countries. Further research is required to 
investigate whether the difference was due to genetic syndromes 
or other reasons.
The male:female IR ratio revealed some important informa-
tion. For example, the ratio of meningioma was smaller in US 
(0.91) than that in Taiwan (0.79). Several factors have been 
explored as potential risk factors for meningioma, including 
exogenous sex hormone exposure (22–25). Though this associa-
tion was unclear and required further investigation, this or other 
currently unknown environmental or behavioral factors could 
be involved in this difference in incidence between these two 
populations. Additionally, the data in Taiwan were restricted 
to a relatively small sample in each specific histological group 
that might result in a bigger fluctuation of rate ratio (Table S4 in 
Supplementary Material).
TaBle 1 | The 1-, 2-, and 5-year survivala for malignant brain and cns tumors by histology and country.
Usb Taiwan
1-Year 2-Year 5-Year 1-Year 2-Year 5-Year
histology N rate (95% ci) rate (95% ci) rate (95% ci) N rate (95% ci) rate (95% ci) rate (95% ci)
Neuronal and mixed 
neuronal glial tumors
82 94.7 (86.6–98.0) 85.7 (74.9–92.0) 71.3 (57.3–81.5) 63 87.3 (76.2–93.4) 71.4 (58.6–80.9) 50.7 (37.4–62.6)
Ependymal tumors 1,781 93.8 (92.6–94.9) 89.3 (87.7–90.8) 82.0 (79.8–84.1) 177 88.1 (82.4–92.1) 83.1 (76.7–87.8) 69.0 (61.3–75.4)
Oligodendroglioma 2,018 93.8 (92.6–94.8) 89.6 (88.1–90.9) 78.7 (76.5–80.8) 283 91.9 (88.0–94.5) 83.0 (78.1–86.9) 70.3 (64.5–75.4)
Germ cell tumors, cysts, 
and heterotopias
556 91.5 (88.8–93.6) 89.0 (86.0–91.5) 83.8 (79.8–87.0) 263 92.0 (88.0–94.7) 87.1 (82.4–90.6) 81.2 (75.7–85.6)
Oligoastrocytic tumors 1,345 88.1 (86.2–89.8) 77.8 (75.3–80.1) 62.8 (59.5–65.9) 194 89.7 (84.5–93.2) 77.3 (70.8–82.6) 61.9 (54.3–68.6)
Anaplastic 
oligodendroglioma
797 83.6 (80.8–86.1) 72.2 (68.8–75.4) 54.6 (50.4–58.6) 150 82.7 (75.6–87.9) 62.0 (53.7–69.2) 35.4 (27.3–43.7)
Embryonal tumors 1,738 81.6 (79.7–83.4) 72.5 (70.2–74.7) 60.9 (58.1–63.5) 342 80.7 (76.1–84.5) 69.3 (64.1–73.9) 54.1 (48.6–59.4)
Meningioma 684 79.3 (76.0–82.2) 70.9 (67.2–74.3) 59.4 (55.2–63.4) 299 81.9 (77.1–85.9) 66.9 (61.2–71.9) 49.9 (43.9–55.6)
Nerve sheath tumors 117 78.3 (69.4–84.9) 71.4 (61.8–79.0) 68.2 (58.3–76.2) 23 60.9 (38.3–77.4) 56.5 (34.3–73.8) 52.2 (30.5–70.0)
Astrocytoma excluding 
GBM and AA
4,101 73.4 (72.0–74.8) 62.9 (61.3–64.4) 48.8 (47.0–50.6) 929 76.0 (73.1–78.6) 63.6 (60.4–66.6) 47.8 (44.5–51.1)
AA 2,313 63.2 (61.1–65.1) 44.8 (42.6–47.0) 27.7 (25.5–29.9) 447 67.8 (63.2–71.9) 45.0 (40.3–49.5) 22.1 (18.1–26.3)
Glioma malignant, NOS 2,821 62.5 (60.6–64.3) 51.9 (49.9–53.8) 44.6 (42.6–46.7) 293 63.8 (58.0–69.0) 43.3 (37.6–48.9) 32.5 (27.1–38.0)
CNS lymphoma 2,898 51.4 (49.5–53.2) 42.6 (40.7–44.5) 31.5 (29.5–33.4) 347 63.1 (57.8–68.0) 47.6 (42.2–52.7) 22.3 (17.8–27.1)
GBM 19,893 37.5 (36.8–38.2) 15.7 (15.2–16.3) 5.0 (4.6–5.4) 2,045 50.3 (48.1–52.4) 24.0 (22.1–25.8) 9.8 (8.5–11.2)
All values 41,144 56.5 (56.0–57.0) 41.1 (40.6–41.6) 30.0 (29.5–30.5) 5,855 68.1 (66.9–69.3) 49.9 (48.6–51.2) 34.3 (33.1–35.6)
aRates are sorted from the largest to the smallest based on the 1-year US data.
bEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: incidence – SEER 18 Regs Research 
Data + Hurricane Katrina Impacted Louisiana Cases, November 2013 Sub (1973–2011 varying) – Linked To County Attributes – Total US, 1969–2012 Counties, National Cancer 
Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2014, based on the November 2013 submission.
AA, anaplastic astrocytoma; CI, confidence interval; CNS, central nervous system; GBM, glioblastoma; NOS, not otherwise specified.
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Ancestral variation might account for differences in incidence 
and survival between the US and Taiwan. Many population-based 
studies have addressed racial and ethnic differences in cancer 
incidence and survival and found that race/ethnicity was a major 
determinant in the incidence and survival in malignant brain and 
CNS tumors (7, 26–29). To further explore this difference, we 
limited our analysis to Asian/Pacific Islanders (APIs) in the US 
and found that the age-adjusted IR of malignant brain and CNS 
tumors for APIs was 4.66 per 100,000, which was still greater than 
that in Taiwan.
Survival after being diagnosed with malignant brain and CNS 
tumors varied significantly depending on the histologic type and 
treatment. We found the overall survival rate in Taiwan to be 
higher than that in the US, which could be partially attributed 
to the larger proportion of GBM in the US. Median survival for 
GBM was ~12–14 months, but the survival rate for those with 
GBM was lower in the US compared with Taiwan. Access to 
health care could also be a factor in survival outcome for brain 
tumor patients in the US. Although provision of health care in 
the US and Taiwan was quite similar, the insurance coverage was 
99% in Taiwan because of the national health insurance system 
(30), whereas the insurance coverage was only 84% in the US (31). 
Several studies have shown that lower cancer survival rates were 
associated with not having health insurance (32–34). Recently, 
the Affordable Care Act has significantly decreased the number 
of citizens without health insurance in the US (35); however, 
whether it would also increase cancer survival rates was yet to 
be determined.
Several limitations were needed to address. First, we selected 
the most common fourteen histology groupings in the final 
analysis since the CBTRUS policy was to suppress data presenta-
tion for cells with counts of <16 in part because the reliability of 
such rates would be questionable. In Taiwan, the cell with count of 
<2 was restricted to report under the HWDC regulation. While 
comparisons between reports were not always straightforward, 
these data represented the majority of brain tumors in both the 
US and Taiwan for the period examined. Second, although the 
relative survival was a standard method to estimate cancer sur-
vival in the absence of other cause of death (36), this study used 
the observed survival rate in both registries due to the difficulty 
to obtain the relative cancer survival in two different registries. 
Additionally, intraobserver variability among histopathologists 
might cause skewed distributions of histopathological subgroups 
and their subsequent analyses in both countries, although we did 
not see the significant different between the diagnostic confirma-
tion between two sites.
cOnclUsiOn
Our findings revealed differences by histological type and grade 
of primary malignant brain and CNS tumors between two 
sites. Comparative studies that minimizing the bias due to case 
7Chien et al. Comparative Analysis of Brain Tumors
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ascertainment and inconsistent report were vital in our under-
standing of brain and CNS tumor burden in these two countries. 
Further studies are required to examine the factors attributed the 
dissimilarity.
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